These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 16364640)

  • 1. 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.
    Kiselyov AS; Semenova M; Semenov VV; Piatnitski E
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1726-30. PubMed ID: 16364640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-(Azolylphenyl)-phthalazin-1-amines: Novel inhibitors of VEGF receptors I and II.
    Kiselyov AS; Semenov VV; Milligan D
    Chem Biol Drug Des; 2006 Dec; 68(6):308-13. PubMed ID: 17177892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinases.
    Nakamura H; Sasaki Y; Uno M; Yoshikawa T; Asano T; Ban HS; Fukazawa H; Shibuya M; Uehara Y
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5127-31. PubMed ID: 16893647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II.
    Kiselyov AS; Semenova M; Semenov VV; Piatnitski E; Ouyang S
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1440-4. PubMed ID: 16321531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase.
    Piatnitski EL; Duncton MA; Kiselyov AS; Katoch-Rouse R; Sherman D; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF
    Bioorg Med Chem Lett; 2005 Nov; 15(21):4696-8. PubMed ID: 16143524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II.
    Kiselyov AS; Piatnitski E; Semenova M; Semenov VV
    Bioorg Med Chem Lett; 2006 Feb; 16(3):602-6. PubMed ID: 16275072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
    Wissner A; Fraser HL; Ingalls CL; Dushin RG; Floyd MB; Cheung K; Nittoli T; Ravi MR; Tan X; Loganzo F
    Bioorg Med Chem; 2007 Jun; 15(11):3635-48. PubMed ID: 17416531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3,4-Disubstituted isothiazoles: novel potent inhibitors of VEGF receptors 1 and 2.
    Kiselyov AS; Semenova M; Semenov VV
    Bioorg Med Chem Lett; 2009 Feb; 19(4):1195-8. PubMed ID: 19124243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2.
    Kiselyov AS; Piatnitski EL; Samet AV; Kisliy VP; Semenov VV
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1369-75. PubMed ID: 17188873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II.
    Duncton MA; Piatnitski EL; Katoch-Rouse R; Smith LM; Kiselyov AS; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1579-81. PubMed ID: 16386418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1-(Azolyl)-4-(aryl)-phthalazines: novel potent inhibitors of VEGF receptors I and II.
    Kiselyov AS; Semenova M; Semenov VV; Piatnitski EL
    Chem Biol Drug Des; 2006 Nov; 68(5):250-5. PubMed ID: 17177884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability.
    Patel N; Sun L; Moshinsky D; Chen H; Leahy KM; Le P; Moss KG; Wang X; Rice A; Tam D; Laird AD; Yu X; Zhang Q; Tang C; McMahon G; Howlett A
    J Pharmacol Exp Ther; 2003 Sep; 306(3):838-45. PubMed ID: 12766257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.
    Usui T; Ban HS; Kawada J; Hirokawa T; Nakamura H
    Bioorg Med Chem Lett; 2008 Jan; 18(1):285-8. PubMed ID: 17983745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template.
    Kiselyov AS; Semenova M; Semenov VV; Milligan D
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1913-9. PubMed ID: 16460936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (1,2,3-Triazol-4-yl)benzenamines: synthesis and activity against VEGF receptors 1 and 2.
    Kiselyov AS; Semenova M; Semenov VV
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1344-8. PubMed ID: 19188066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.
    Lee K; Jeong KW; Lee Y; Song JY; Kim MS; Lee GS; Kim Y
    Eur J Med Chem; 2010 Nov; 45(11):5420-7. PubMed ID: 20869793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tricyclic azepine derivatives: pyrimido[4,5-b]-1,4-benzoxazepines as a novel class of epidermal growth factor receptor kinase inhibitors.
    Smith L; Piatnitski EL; Kiselyov AS; Ouyang X; Chen X; Burdzovic-Wizemann S; Xu Y; Pan W; Chen X; Wang Y; Rosler RL; Patel SN; Chiang HH; Milligan DL; Columbus J; Wong WC; Doody JF; Hadari YR
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1643-6. PubMed ID: 16412636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.
    Kuo GH; Wang A; Emanuel S; Deangelis A; Zhang R; Connolly PJ; Murray WV; Gruninger RH; Sechler J; Fuentes-Pesquera A; Johnson D; Middleton SA; Jolliffe L; Chen X
    J Med Chem; 2005 Mar; 48(6):1886-900. PubMed ID: 15771433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.
    Wissner A; Floyd MB; Johnson BD; Fraser H; Ingalls C; Nittoli T; Dushin RG; Discafani C; Nilakantan R; Marini J; Ravi M; Cheung K; Tan X; Musto S; Annable T; Siegel MM; Loganzo F
    J Med Chem; 2005 Dec; 48(24):7560-81. PubMed ID: 16302797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase.
    Sisko JT; Tucker TJ; Bilodeau MT; Buser CA; Ciecko PA; Coll KE; Fernandes C; Gibbs JB; Koester TJ; Kohl N; Lynch JJ; Mao X; McLoughlin D; Miller-Stein CM; Rodman LD; Rickert KW; Sepp-Lorenzino L; Shipman JM; Thomas KA; Wong BK; Hartman GD
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1146-50. PubMed ID: 16368234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.